Saturday 17 October 2026
Export EFTR’s income statement to Excel — free account
eFFECTOR Therapeutics, Inc.
EFTR Healthcare Biotechnology
0.00
0.00
NaN
Follow EFTR
eFFECTOR Therapeutics, Inc. (EFTR) P/E ratio
eFFECTOR Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 4.4× (October 2022) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2022 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2020 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Dec 2022 | 0.0× | — |
| Sep 2022 | 3.8× | 144.38% |
| Jun 2022 | 1.6× | — |
| Dec 2021 | 0.0× | — |
| 4 more quarters | Free account |
Against its own ten years
Low 0.0×
High 4.4×
Ten-year median
0.0×
Current reading's percentile
91
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| BDRX Biodexa Pharmaceuticals PLC Unsponsored ADR compare | n/m |
| VRPX Virpax Pharmaceuticals, Inc. compare | n/m |
| CDT CDT Equity Inc. compare | n/m |
| VINC Vincerx Pharma, Inc. compare | n/m |
| ATXI Avenue Therapeutics, Inc. compare | n/m |
| SEELQ Seelos Therapeutics, Inc. compare | n/m |
| EFTR eFFECTOR Therapeutics, Inc. | n/m |
| CERO CERo Therapeutics Holdings, Inc. compare | 0.0× |
| SCNI Scinai Immunotherapeutics Ltd. Sponsored ADR compare | 0.0× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)